{"doi":"10.1093/cid/ciad199","title":"Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection","abstract":"BACKGROUND: People with human immunodeficiency virus (PWH) are at increased risk for comorbidities, and plasma interleukin 6 (IL-6) levels are among the most robust predictors of these outcomes. Tocilizumab (TCZ) blocks the receptor for IL-6, inhibiting functions of this cytokine. METHODS: This was a 40-week, placebo-controlled, crossover trial (NCT02049437) where PWH on stable antiretroviral therapy (ART) were randomized to receive 3 monthly doses of TCZ or matching placebo intravenously. Following a 10-week treatment period and a 12-week washout, participants were switched to the opposite treatment. The primary endpoints were safety and posttreatment levels of C-reactive protein (CRP) and CD4+ T-cell cycling. Secondary endpoints included changes in inflammatory indices and lipid levels. RESULTS: There were 9 treatment-related toxicities of grade 2 or greater during TCZ administration (mostly neutropenia) and 2 during placebo administration. Thirty-one of 34 participants completed the study and were included in a modified intent-to-treat analysis. TCZ reduced levels of CRP (median decrease, 1819.9 ng/mL, P < .0001; effect size, 0.87) and reduced inflammatory markers in PWH, including D-dimer, soluble CD14, and tumor necrosis factor receptors. T-cell cycling tended to decrease in all maturation subsets after TCZ administration, but was only significant among naive CD4 T cells. Lipid levels, including lipid classes that have been related to cardiovascular disease risk, increased during TCZ treatment. CONCLUSIONS: TCZ is safe and decreases inflammation in PWH; IL-6 is a key driver of the inflammatory environment that predicts morbidity and mortality in ART-treated PWH. The clinical significance of lipid elevations during TCZ treatment requires further study. Clinical Trials Registration. NCT02049437.","journal":"Clinical Infectious Diseases","year":2023,"id":332290,"datarank":0.7322218982193167,"base_score":3.258096538021482,"endowment":3.258096538021482,"self_citation_contribution":0.4887144807032224,"citation_network_contribution":0.24350741751609437,"self_endowment_contribution":0.4887144807032224,"citer_contribution":0.24350741751609437,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":20,"citers_with_citation_signal":13,"citers_with_endowment":13,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.959,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02049437"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":333572,"name":"Carey L. Shive","orcid":"0000-0002-6908-1246","position":1,"is_corresponding":false},{"id":447066,"name":"Zhengyi Chen","orcid":"0000-0002-2745-4454","position":2,"is_corresponding":false},{"id":67977,"name":"Curtis Tatsuoka","orcid":"0000-0001-9991-4440","position":3,"is_corresponding":false},{"id":380902,"name":"Emily Bowman","orcid":"0000-0003-1783-0361","position":4,"is_corresponding":false},{"id":98921,"name":"Chris T. Longenecker","orcid":"0000-0002-9468-0179","position":5,"is_corresponding":false},{"id":247284,"name":"Grace A. McComsey","orcid":"0000-0003-2690-8888","position":6,"is_corresponding":false},{"id":655616,"name":"Brian Clagett","orcid":"0009-0006-4046-125X","position":7,"is_corresponding":false},{"id":1031648,"name":"Dominic Dorazio","orcid":null,"position":8,"is_corresponding":false},{"id":333577,"name":"Michael L. Freeman","orcid":"0000-0002-7690-5258","position":9,"is_corresponding":false},{"id":333573,"name":"Scott F. Sieg","orcid":"0000-0002-1769-8682","position":10,"is_corresponding":false},{"id":655615,"name":"Daniela Moïsi","orcid":"0000-0003-2326-7683","position":11,"is_corresponding":false},{"id":434574,"name":"Donald D. Anthony","orcid":"0000-0002-1226-5976","position":12,"is_corresponding":false},{"id":593197,"name":"Jeffrey M. Jacobson","orcid":"0000-0003-0725-249X","position":13,"is_corresponding":false},{"id":525069,"name":"Sharon L. Stein","orcid":"0000-0002-5290-3805","position":14,"is_corresponding":false},{"id":381047,"name":"Leonard H. Calabrese","orcid":"0000-0002-1789-4923","position":15,"is_corresponding":false},{"id":328573,"name":"Alan Landay","orcid":"0000-0001-9645-1356","position":16,"is_corresponding":false},{"id":498021,"name":"Charles Flexner","orcid":"0000-0002-4495-5349","position":17,"is_corresponding":false},{"id":1059004,"name":"Keith W. Crawford","orcid":null,"position":18,"is_corresponding":false},{"id":330622,"name":"Edmund V. Capparelli","orcid":"0000-0002-1630-0505","position":19,"is_corresponding":false},{"id":333576,"name":"Benigno Rodríguez","orcid":"0000-0001-9736-7957","position":20,"is_corresponding":false},{"id":262177,"name":"Michael M. Lederman","orcid":"0000-0001-9247-8025","position":21,"is_corresponding":false},{"id":295813,"name":"Nicholas Funderburg","orcid":"0000-0003-3113-1217","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-19T01:09:30.139849Z","pmid":"37011013","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}